 |
Dasatinib |
|---|---|
| Trade Name | Sprycel |
| Orphan Indication | Acute lymphoblastic leukemia |
| USA Market Approval | USA |
| USA Designation Date | 2005-11-18 00:00:00 |
| Sponsor | Bristol-Myers Squibb Company;5 Research Parkway;Wallingford, Connecticut, 06492 |
Related Access Program
Novartis Pharmaceuticals – Acute Lymphoblastic Leukemia
University of California, San Francisco – Acute Lymphoblastic Leukemia
ERYtech Pharma – Acute Lymphoblastic Leukemia
University of California, San Francisco – Acute lymphoblastic leukemia
ERYtech Pharma – Acute lymphoblastic leukemia
Amgen – Acute lymphoblastic leukemia